Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 5Sarcoma 4Genitourinary 3Gastrointestinal 3Dermatologic 3Endocrine 2CNS 2Thoracic 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Breast 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Somatostatinoma 1Multiple Endocrine Neoplasia Type 1 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 17Specimen Handling 13lutetium Lu 177 dotatate 7gallium Ga 68 dotatate 7Cisplatin 7cabozantinib 6pazopanib 5Sorafenib 5Fluorodeoxyglucose F18 5Everolimus 5Etoposide 4romidepsin 3olaparib 3fluorodopa F 18 3cixutumumab 3X-Rays 3Temozolomide 3Sunitinib 3Radiotherapy 3Nivolumab 3Ipilimumab 3Iodine-131 3CTLA-4 Antigen 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tipifarnib 2belinostat 2aldesleukin 2aflibercept 2Vorinostat 2Trastuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × aflibercept × Endocrine × Clear all
NCT02101918 2020-03-23

Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 10 charts
Endocrine

Somatostatinoma, Multiple Endocrine Neoplasia Type 1

NCT00729157 2017-03-15

Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

National Cancer Institute (NCI)

Phase 2 Completed
41 enrolled 10 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡